Cincor Pharma Inc PT Lowered to $24 at Piper Sandler https://www.investing.com/news/pro/cincor-pharma-inc-pt-lowered-to-24-at-piper-sandler-432SI-3009951
There's a Lot to Love About Mineralys' Valentine's Day IPO It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volume, there certainly appears to be a lot of interest in the budding clinical-stage biopharmaceutical company.
AstraZeneca Promises Blockbuster Product as COVID Threat Fades Demand for COVID-19 vaccines has dropped as the pandemic enters its fourth year, but AstraZeneca (NASDAQ:AZN) says it has blockbuster projects in development that are set to make billions of dollars. We expect to start 30 phase three clinical trials this year, of which we expect to hopefully land more than 10 products that will be blockbuster products, or products that will hopefully achieve more than a billion in revenue, Chief Financial Officer Aradhana Sarin told media outlets Thursday. Really its the revenue growth on the top line but also the reinvestment in the business that continues to fuel innovation and continues to fuel long term growth, she added. The British-Swedish pharmaceutical company forecast growth in earnings and revenue for 2023 Thursday, with its underlying businesses helping the company to post $901 million in net profit for the fourth quarter. AstraZeneca CEO Pascal Soriot shared details of some of the drugs currently undergoing phase three trials in a media conference Thursday.
AstraZeneca starts tender offer to acquire CinCor AstraZeneca (AZN) began a tender offer for its up to $1.8B acquisition of CinCor Pharma (CINC).The British pharma giant will acquire all outstanding shares of CinCor for $26 per share…
CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95? CinCor Pharma Inc. (NASDAQ:CINC) price on Friday, January 13, fall -0.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $28.95. A look at the stock’s price movement, the close in the last trading session was $29.07, moving within a range at $28.765 and $29.05. Turning to its … CinCor Pharma Inc. (CINC): Is It Worth A Small Bite At $28.95? Read More »
Barclays Downgrades Cincor Pharma Inc to Equalweight https://www.investing.com/news/pro/barclays-downgrades-cincor-pharma-inc-to-equalweight-432SI-2978799
CINCOR PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CinCor Pharma, Inc. (NasdaqGM: CINC) to AstraZeneca. Under the terms of the proposed transaction, shareholders of CinCor will receive $26.00 in cash plus a non-tradable contingent value right of $10.00 (payable upon a specified regulatory
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc. NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by…
SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc. NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Company") (NASDAQ: CINC), in connection with the proposed acquisition of the Company by AstraZeneca PLC (NASDAQ: AZN) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $26.00 in cash for each share of CinCor common stock owned, plus a non-tradable contingent value right ("CVR") of $10.00.
Why Is CinCor (CINC) Stock Up 138% Today? CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.